Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 20Genitourinary 19Gastrointestinal 14Myeloid 12Lymphoid 10Dermatologic 10Plasma cell 7Thoracic 3Endocrine 2Sarcoma 1Other solid neoplasm 1Other neoplasm 1NET 1Head & Neck 1Gynecologic 1CNS 1

Conditions

Central Nervous System Neoplasms 1Brain Neoplasms 1

Interventions

Temozolomide 400Radiotherapy 239Bevacizumab 185Magnetic Resonance Spectroscopy 168Radiosurgery 142Cyclophosphamide 95Irinotecan 79Carboplatin 79Etoposide 78Radiation 76pembrolizumab 70Nivolumab 59Surgical Procedures, Operative 57Filgrastim 56Specimen Handling 53Cisplatin 50Blood Specimen Collection 46Topotecan 45Vincristine 43Melphalan 38Radiotherapy, Intensity-Modulated 36Pemetrexed 36Lomustine 36Ipilimumab 36Everolimus 35Magnetic Resonance Imaging 34Erlotinib Hydrochloride 34Drug Therapy 34Surveys and Questionnaires 33sargramostim 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Interferon-alpha × CNS × Clear all
NCT00002965 2023-12-22

Interferon Alfa in Treating Patients With Recurrent Unresectable Meningiomas and Malignant Meningiomas

M.D. Anderson Cancer Center

Phase 2 Completed
16 enrolled
CNS

Brain Neoplasms, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡